1 Prevalence and Outcome of Adults with Congenital Heart Disease

2 and Coronary Artery Disease

- 3 Haiyang Li MD^{a,c*}, Yan Yan MD^{b,c*}, Shipan Wang MD^{a,c*}, Mingyu Sun MD^{a,c*}, Sichong
- 4 Qian, MD^{a,c}, Yuan Xue, MD^{a,c}, Hongjia Zhang, MD^{a,c#}
- 5
- ^a Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University,
- 7 Beijing, China
- ^b Center for Coronary Artery Disease, Department of Cardiology, Beijing Anzhen Hospital,
- 9 Capital Medical University, Beijing, China
- ^c National Clinical Research Center for Cardiovascular Diseases, Beijing, China
- 11
- 12 * These authors contributed equally to this study.
- 13 #Address for correspondence:
- 14 Hongjia Zhang, MD, PhD
- 15 Beijing Anzhen Hospital, Capital Medical University
- 16 2 Anzhen Road, Chaoyang District, Beijing, China, 100029
- 17 Email: zhanghongjia722@ccmu.edu.cn
- 18

19 Running title: Prevalence and Outcome of ACHD and CAD

- 20 Word count: 3219 words
- 21 Figure: 2
- 22 Table: 3

1 ABSTRACT

BACKGROUND Little is known about the prevalence of outcome in patients with coronary artery disease (CAD) among adults with congenital heart disease (ACHD). The objectives of this study were to determine rates of ACHD and factors associated with outcomes among adults with CAD in a contemporary cohort within the China.

METHODS Using pragmatic data from the Prospective Registry of the Current Status of
Care for Patients with Coronary Artery Disease database, between January and May 2022,
we stratified all CAD patients with comorbid ACHD or not. Using logistic regression
method, we explored the risk factors associated with lower risk of mortality and stroke. We
constructed a matching sub-cohort as sensitive analysis.

11 **RESULTS** Of 10.517 evaluable patients 189 (1.8%) were with a diagnosis of ACHD, and were more female, more frequent with a history of atrial fibrillation, had a lower 12 hemoglobin level at admission but less likely to have hypertension or smoking history than 13 those without ACHD. In-hospital mortality before discharge was higher in patients with 14 ACHD compared with no ACHD in the whole population (1.06% vs. 0.28%, p=0.05) and 15 matched population (1.06% vs. 0.13%, p=0.04). Acute myocardial infarction (54.8%) 16 17 represented the most common cause of death among all cohort, whereas 100% deaths among ACHD were due to ischemic stroke (2 cases). 18

19 CONCLUSIONS ACHD was associated with a higher rate of mortality, which stroke 20 complications contribute most. Future studies are needed to improve the acknowledge of 21 underlying stroke mechanisms and prognosis in this special population.

1 KEY WORDS Adult congenital heart disease; Coronary artery disease; Pragmatic registry;

2 In-hospital Outcome

1 INTRODUCTION

Given the success of modern cardiology care, congenital heart disease (CHD) has been 2 3 transformed from a deadly condition into a treatable disorder, with an increasing need to deliver age-appropriate medical care¹. Numerous studies have demonstrated that residual 4 defects contribute substantially to long-term morbidity²⁻⁴. The current Guidelines for Adults 5 with Congenital Heart Disease (ACHD) developed for general cardiologists and the 6 community of ACHD specialists focusing on surgical and percutaneous interventions 7 process^{5,6}. However, somewhat surprising is the fact that recommendations have largely 8 been classified as Class I with a level of evidence at B or C, indicating the mismatch 9 between clinical needs and quality of supportive data⁵. 10

As a field which lags significantly behind other adult populations, specialized study performing on ACHD are warranted to generate comparable evidence to non-CHD population. In the present study, we aimed to provide a general overview of ACHD in the coronary artery disease (CAD) population using a pragmatic registry. We also aim to provide an outlook on the potential prognostic factors and outcomes in this population.

16 **METHODS**

17 Study design and patient selection

Data from the Prospective Registry of the Current Status of Care for Patients with Coronary Artery Disease database were used in the study. Launched on January 17th, 2022, the project (clinicaltrial.gov NCT 05337319) is a nationwide, pragmatic registry including patients with a principal discharge diagnosis of coronary artery disease (CAD). The registry

1 is a program of the National Clinical Research Center for Cardiovascular Disease in Beijing 2 Anzhen hospital, focusing on quality improvement efforts for CAD care by routinely collected electronic health records. Briefly, the in-hospital patients were recruited 3 consecutively in collaborative hospitals every month. Patient were eligible for enrollment 4 with a principal discharge diagnosis of CAD, including ST elevated myocardial infarction, 5 6 non-ST-segment elevation myocardial infarction, unstable angina pectoris, and stable 7 coronary artery disease. The protocol was approved by the Ethics Committee of Beijing 8 Anzhen Hospital, Capital Medical University.

Patient-level data including demographics, medical history, physical examination, 9 laboratory findings, medical treatment, procedural details, and in-hospital outcomes were 10 collected via electronic medical records (EMR) and death registry system databases. 11 12 Diagnosis and procedural details were entered into the database by medical staffs and coded by trained data abstractors. Data quality including accuracy, completeness, and 13 14 consistency was monitored monthly by the study management group. All consecutive 15 in-hospital patients with CAD at discharge in the database between January 17th, 2022 and May 31th, 11023 were included in this study. Patients who were not older than 18 years 16 were excluded from the analysis. 17

18 Definitions of variables

19 ICD-10 diagnosis codes and ICD-9-CM-3 procedural codes were utilized for variable 20 collection^{7,8}. CAD and CHD were defined in accordance with the guidelines published by 21 the Chinese society of cardiology and recorded by doctors on original medical records⁹. 22 Patients were considered to have CHD, such as atrial septal defect, ventricular septal defect,

5

or patent ductus arteriosus, if those had been documented in admission or detected by
echocardiogram during hospitalization¹⁰. An estimated glomerular filtration rate lower than
60 mL/min per 1.73 m² was defined as renal insufficiency. Patients were classified as
ACHD group if they had firmed evidence of ACHD during their hospitalization for treating
CAD. Patients who were not recognized any congenital cardiac defect were defined as "no
ACHD".

7 Endpoints

The primary endpoint was in-hospital mortality. Cardiovascular death was defined as any 8 death with a clear relationship to underlying coronary heart disease (including death, 9 secondary to acute MI, sudden death, unobserved and unexpected death, resuscitated out of 10 11 hospital cardiac arrest that does not survive to hospital discharge), stroke, and other death that cannot definitely be attributed to a non-CV cause. Stroke was defined as a new 12 neurologic deficit during the index event hospitalization. Both ischemic and hemorrhagic 13 stroke will be considered as an endpoint and differentiated into the 2 types of events. 14 Pneumonia was defined as new documentation in the medical record based on supportive 15 laboratory findings and radiologic evidence. All these endpoints were documented in 16 17 medical records by clinical doctors during hospitalization.

18 Statistical analysis

Baseline characteristics and procedural details of included patients are described.
Continuous variables are presented as mean and standard deviation (SD) if a normal
distribution, and as a median and interquartile range (IQR) if skewed. Categorical variables

are presented as frequency and percentage. T-test or Kruskal-Wallis test for continuous
 variables, and Chi-square test for categorical variables were used to test for statistically
 significant differences between the ACHD versus No ACHD groups.

We used logistic regression method to explore the potential risk factors of endpoints.
The univariate logistic models were built by each candidate that showed a significant
difference between the ACHD and no ACHD groups. Odd ratios (OR) and 95% confidence
intervals (CI) were calculated and reported.

8 Considering the unbalanced number of enrolled patients between two groups, we 9 constructed a matching sub-cohort from this population to conduct the sensitive analysis. In 10 detail, we used all ACHD patients as 'cases' and selected 4 'controls' for each of them from 11 the No ACHD patients randomly. Each control had a same age and sex with the matched 12 case. We applied logistic models in this matched cohort to verify the association between 13 potential risk factors and endpoints.

The reference was used as No ACHD group in all analyses. All tests were two-sided, and a *p* value of less than 0.05 was considered with statistical significance. All statistical analyses were performed by SAS version 9.4 (SAS Institute Inc; Cary, NC).

17 **RESULTS**

18 Patient characteristics, treatments, and procedural details

Up to May 31, 2022, a total of 11,023 patients with cleaned data were enrolled in the study.
Based on the principal discharge diagnosis, 10,519 patients with CAD during the study
period were identified. After excluding 2 patients younger than 18 years, 10,517 patients

were included in the study, of whom 189 (1.8%) were diagnosed with ACHD. The type of
CHD in ACHD group is shown in Figure 1. 750 No ACHD patients were selected as
controls (6 ACHD patients could only find 3 controls for each).

Patient baseline characteristics and procedural details were shown in **Table 1**. Patients with ACHD and CAD were more female, more frequent with a medical history of atrial fibrillation, and had a lower hemoglobin level at admission. However, they were less likely to have atherosclerotic cardiovascular disease (ASCVD) risk factors such as hypertension or smoking. 124 cases (65.6%) of atrial septal defect were the commonest comorbidity with CAD. In the matched cohort, baseline characteristics between the two groups were well balanced except for the history of hypertension (56.1% vs 67.1%, p<0.001).</p>

The most frequently used thromboprophylaxis for ACHD was anticoagulant, with weak antiplatelet therapy than no ACHD group. This drug discrimination was observed both at admission and discharge. The ACHD patients underwent CABG more frequently than the no ACHD group (14.3% vs 9.4%, p=0.02), but less received PCI (29.1% vs 44.1%, p<0.001). Moreover, compared with no ACHD, the ACHD patients had a less frequent use of statin at discharge (74.6% vs 86.7%, p<0.001). Similar results were found in the matched cohort.

18 In-hospital clinical outcomes

Table 2 shows in-hospital outcomes in the two groups. In-hospital mortality before discharge was higher in patients with ACHD compared with no ACHD in the whole population (1.06% vs. 0.28%, p=0.05) and matched population (1.06% vs. 0.13%, p=0.04).
The overall incidence of in-hospital cardiovascular death was 0.28% (29 cases); the

incidence of cardiovascular death was higher in patients with ACHD than in those without
(1.06% vs. 0.26%; p=0.04). Compared with no ACHD, ACHD group has an increased risk
of in-hospital stroke (3.17% vs 0.93%, p<0.001), ischemic stroke and intracerebral
hemorrhage; while the difference in ischemic stroke was no longer significant in the
matched population. The incidence of lung infection during hospitalization was similar in
the two groups (0.53% vs. 0.44%, p=0.85).

The causes of death are presented in Figure 2. The most common causes of death
among all adults with CAD in the death cohort were acute myocardial infarction (54.8%),
cardiac shock (12.9%) and cardiac arrest (9.6%). The 2 deaths among those with ACHD
were due to ischemic stroke (100%).

11 Risk factors of death and stroke

In the logistic regression model including baseline characteristics with a statistically 12 significant difference between groups, anemia at admission (OR: 4.57, 95% CI, 1.9–11.01), 13 acute myocardial infarction (OR: 19.15, 95% CI, 8.77-41.82) were independent risk factors 14 of mortality (Table 3). Whereas, the PCI intervention (OR: 0.38, 95% CI, 0.15–0.95) and 15 CABG (OR: 19.15, 95% CI, 8.77-41.82) were identified as protectors of mortality. 16 17 Compared with patients without ACHD, the risk of stroke markedly increased in patients with ACHD (OR: 2.89, 95% CI, 1.22–6.87). Moreover, the history of hypertension showed 18 a strong association with in-hospital stroke (OR: 2.9, 95% CI, 1.74-4.83). 19

20 **DISCUSSION**

Among 10,517 hospitalized CAD patients in the real-world cohort who were analyzed in

this study, ACHD was associated with a higher rate of mortality driven by stroke
complications. Furthermore, no differences were found between ACHD and no ACHD
patients with regard to the risk of pneumonia.

Nowadays, the medical need in patients with CHD is shifted from survival to beyond 4 survival^{11,12}. Truly assessing the long-term impact of CHD is mandatory for people living 5 with chronic conditions and their caregivers¹³. Whereas consideration and overcoming 6 7 above mentioned challenges of the utmost importance in guidelines, comprehensive registries with contemporary CHD data are warrant¹¹. In a retrospective, a single-center 8 database of patient older than 40 year and patent foramen ovale (PFO) in Toronto, 180 9 patients (84.9%) did concurrent coronary angiography with PFO disclosure¹⁴. A low 10 prevalence of moderate-to-severe CAD (12.8%) was identified by coronary angiography 11 and rare (0.6%) underwent concurrent angioplasty. A report from a standard adult 12 cardiovascular center between April 2012 and August 2019, only 58 patients with the 13 diagnosis of ACHD have been hospitalized¹⁵. Among them, only 6 (10.3%) were comorbid 14 15 CAD. Lately, a national wide registry from Dutch demonstrated an increased CAD risk in ACHD patients compared to the general population, especially in youth but not in women 16 older than 65 years or men older than 50 years¹⁶. However, these data cannot reach an 17 established opinion regarding the accurate rate of comorbid CAD with ACHD, because of 18 19 the diversity of the studied population. In our database using routine medical data sources, a real-world cohort of coronary artery disease, showed 1.8% CAD patients with ACHD. As 20 21 the high incidence of mortality was observed in the ACHD and CAD population, which highlights the complexity mechanisms other than atherosclerosis contribute to the high 22

mortality associated with CHD in this population. Although our observational study might
be influenced by potentially unmeasured confounding variables, the data including
conversational, interventional, and surgical data shed light on this important remark.

Recently, a higher rate of recurrent ischemic events was observed in ACHD population, 4 especially of neurocognitive complications^{17,18}. Analysis from large cohort of adults with 5 6 mild-to-moderate CHD of UK-biobank demonstrated measurable neurocognitive deficits. 7 These findings indicated a transition cerebro- and cardiovascular process for CHD individuals moving from pediatric to adult¹⁸. In a patient-level pooled analysis of a 8 randomized trial, young adults with cryptogenic strokes of undetermined source (ESUS) 9 showed a low rate of recurrence stroke than older adults with ESUS⁴. Whereas PFO was 10 detected in 50% of participants during follow-up, which may represent an incidental risk 11 factor for stroke occurrence. Shah P, et al. systematic reviewed 386 cases with a thrombus 12 straddling a PFO from 359 publications³. In their research, acute myocardial infarction but 13 14 not ischemic stroke was associated with an 8-fold increased risk of in-hospital mortality. 15 Analysis of individual patient data comprised of observational and randomized studies focused on PFO population. These results indicated atrial septal aneurysm as an important 16 predictor of recurrent stroke, suggesting the need for risk stratification and procedural 17 18 intervention in this population. In line with the previous studies, an increased rate of stroke was observed in ACHD group, suggesting the need for future studies to improve 19 acknowledge of underlying stroke mechanisms in this special population. A priori, it may 20 21 have been hypothesized that surgical impairment would reduce the rate of acute thrombotic complications which resulting ischemic events. The on-going trials (NCT03690518, 22

1 NCT04902768, NCT04288596) will provide firmer information on this question¹⁹.

2 In our study, comorbid ACHD and history of hypertension were associated with a higher rate of in-hospital stroke. A report from CHD centers in North Carolina from 2008 to 3 2013 including 629 CHD patients dead with age at over 20 years, showed causes of death 4 differed by lesion severity²⁰. ACHD patients with severe lesions commonly died from 5 6 underlying CHD, whereas those with non-severe CHD more commonly died from ischemic 7 heart disease or malignancy. Hypertension and hyperlipidemia were prevalent at high rates 8 among ACHD, indicating longitudinally medical care for ACHD should focus on traditional ASCVD risk factors. Latterly, Swedish National Patient Register identified 9 17,189 ACHD patients and 180,131 matched controls describing the risk of myocardial 10 infarction (MI) in ACHD²¹. In line with the national report, our data shows ACHD patients 11 12 died commonly due to new-onset heart failure, or death after the index MI. Recognizing and managing the modifiable ASCVD risk factors are crucial to reduce morbidity and 13 14 mortality in this special population. More detailed studies of these links are warranted to 15 establish potential causality and pathogenesis ought to investigate the predictor and outcomes of ischemic event including MI or stroke in ACHD population. 16

Several important limitations of this study should be noted. Consisted with all observational studies, inherent limitations and residual confounding exist, our results should be considered as hypothesis-generating. Nevertheless, the study provides pragmatic data reflecting contemporary management in ACHD patients with CAD in China. Second, we did not include variables related to invasive extracorporeal circulation in the multivariable logistic regression models exploring the risk factor of stroke, because of

12

overfitting effect due to the small number of events. Third, we did not have detailed information on anticoagulation in the periprocedural period, which may represent a potential bias against the main objective of our study. Fourth, there were no follow-up data about the influence of stroke on mortality, disability, and quality of life. Despite the limitations, this is a pool of data picturing the view of ACHD in patients with CAD in the contemporary era.

7 CONCLUSIONS

Among CAD patients with comorbid ACHD, non-severe CHD was common and ACHD
was associated with an increased risk of developing stroke or death. Longitudinal study on
modifiable ASCVD risk factors in this special population are awaited.

11 SOURCES OF FUNDING

The prospective registry of the current status of care for patients with coronary artery disease has been funded by Beijing Anzhen hospital and National Clinical Research Center for Cardiovascular Diseases for quality improvement initiatives through an independent grant.

16 CONFLICT OF INTEREST AND FINANCIAL DISCLOSURE STATEMENT

Dr. Yan was funded by grants from the National Natural Science Foundation of China
(82100260) and Beijing Hospitals Authority Youth Program (QML20210605). Dr. Li was
funded by National Natural Science Foundation of China (82070483), Beijing Municipal
Administration of Hospitals Clinical Medicine Development of Special Funding Support

- 1 (XMLX202107), Beijing Municipal Commission of Education (KM202110025014),
- 2 Beijing Municipal Science and Technology Commission (Z211100002921010). The other
- 3 authors have no conflicts of interest to declare.

4 **CONTRIBUTION**

- 5 HL and YY contributed to the manuscript draft and analysis; YY, SQ and HZ contributed to
- 6 the manuscript development; SW, YX and HZ were responsible for overseeing and
- 7 monitoring the implementation of the registry; all authors critically reviewed the
- 8 manuscript and approved the final version.

9

1 **REFERENCES**

2	1.	Bredy C, Ministeri M, Kempny A, et al. New York Heart Association (NYHA)					
3		classification in adults with congenital heart disease: relation to objective measures of					
4		exercise and outcome. Eur Heart J Qual Care Clin Outcomes 2018;4:51-8.					
5	2.	Scott M, Neal AE. Congenital Heart Disease. Prim Care 2021;48:351-66.					
6	3.	Shah P, Jimenez-Ruiz A, Gibson A, et al. Association between acute myocardial					
7		infarction and death in 386 patients with a thrombus straddling a patent foramen					
8		ovale. International journal of cardiology 2021;342:1-6.					
9	4.	Perera KS, de Sa Boasquevisque D, Rao-Melacini P, et al. Evaluating Rates of					
10		Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of					
11		Undetermined Source: The Young ESUS Longitudinal Cohort Study. JAMA Neurol					
12		2022;79:450-8.					
13	5.	Marelli A, Beauchesne L, Colman J, et al. Canadian Cardiovascular Society 2022					
14		Guidelines for Cardiovascular Interventions in Adults With Congenital Heart Disease.					
15		Can J Cardiol 2022;38:862-96.					
16	6.	Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the					
17		Management of Adults With Congenital Heart Disease: A Report of the American					
18		College of Cardiology/American Heart Association Task Force on Clinical Practice					
19		Guidelines. Circulation 2019;139:e698-e800.					
20	7.	Rockower SJ. ICD-10: how did we get here, or what are we doing? Md Med					
21		2014;15:12-3.					
22	8.	Wang D, Wu ZQ, Wang W, et al. [Comprehensive analysis of unplanned abdominal -					
23		pelvic reoperations in Peking University Cancer Hospital and Institute from 2008 to					
24		2018]. Zhonghua Wei Chang Wai Ke Za Zhi 2019;22:869-75.					
25	9.	Chinese Cardiovascular Society 2021 Guidelines for Cardiovascular Interventions in					
26		Congenital Heart Disease, Zhonghua Yixue Za Zhi, 2021,101(38): 3054-3076.					
27	10.	Writing G, Sachdeva R, Valente AM, et al.					
28		ACC/AHA/ASE/HRS/ISACHD/SCAI/SCCT/SCMR/SOPE 2020 Appropriate Use					
29		Criteria for Multimodality Imaging During the Follow-Up Care of Patients With					

15

Congenital Heart Disease: A Report of the American College of Cardiology Solution
 Set Oversight Committee and Appropriate Use Criteria Task Force, American Heart
 Association, American Society of Echocardiography, Heart Rhythm Society,
 International Society for Adult Congenital Heart Disease, Society for Cardiovascular
 Angiography and Interventions, Society of Cardiovascular Computed Tomography,
 Society for Cardiovascular Magnetic Resonance, and Society of Pediatric
 Echocardiography. J Am Soc Echocardiogr 2020;33:e1-e48.

- 8 11. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the
 9 management of adult congenital heart disease. European heart journal
 10 2021;42:563-645.
- Chessa M, Brida M, Gatzoulis MA, et al. Emergency department management of
 patients with adult congenital heart disease: a consensus paper from the ESC Working
 Group on Adult Congenital Heart Disease, the European Society for Emergency
 Medicine (EUSEM), the European Association for Cardio-Thoracic Surgery
 (EACTS), and the Association for Acute Cardiovascular Care (ACVC). European
 heart journal 2021;42:2527-35.
- 17 13. Warnes CA. Adult congenital heart disease: the challenges of a lifetime. European
 heart journal 2017;38:2041-7.
- Frankfurter C, Muthuppalaniappan AM, Gorocica-Romero R, et al. Coronary Artery
 Disease in Adults Undergoing Percutaneous Patent Foramen Ovale Closure
 Following Cryptogenic Stroke. J Invasive Cardiol 2021;33:E870-E6.
- Toyoda S, Sakuma M, Abe S, Nakajima T, Inoue T. Coronary artery disease in
 patients with adult congenital heart disease. International journal of cardiology
 2020;304:35-6.
- Kuijpers JM, Vaartjes I, Bokma JP, et al. Risk of coronary artery disease in adults
 with congenital heart disease: A comparison with the general population.
 International journal of cardiology 2020;304:39-42.
- Wang T, Chen L, Yang T, et al. Congenital Heart Disease and Risk of Cardiovascular
 Disease: A Meta-Analysis of Cohort Studies. Journal of the American Heart
 Association 2019;8:e012030.

1	18.	Perrotta ML, Saha P, Zawadzki R, et al. Adults With Mild-to-Moderate Congenital
2		Heart Disease Demonstrate Measurable Neurocognitive Deficits. Journal of the
3		American Heart Association 2020;9:e015379.

- 4 19. Amedro P, Gavotto A, Legendre A, et al. Impact of a centre and home-based cardiac
 5 rehabilitation program on the quality of life of teenagers and young adults with
 6 congenital heart disease: The QUALI-REHAB study rationale, design and methods.
 7 International journal of cardiology 2019;283:112-8.
- 8 20. Goldstein SA, D'Ottavio A, Spears T, et al. Causes of Death and Cardiovascular
 9 Comorbidities in Adults With Congenital Heart Disease. J Am Heart Assoc
 10 2020;9:e016400.
- Fedchenko M, Mandalenakis Z, Giang KW, Rosengren A, Eriksson P, Dellborg M.
 Long-term outcomes after myocardial infarction in middle-aged and older patients
 with congenital heart disease-a nationwide study. Eur Heart J 2021;42:2577-86.
- 14
- 15

1 FIGURE LEGENDS

- 2 Figure 1
- 3 Type of CHD in ACHD group.
- 4 CHD, congenital heart disease; ACHD, congenital heart disease
- 5
- 6 Figure 2
- 7 Causes of death among study cohort.
- 8 ACHD, congenital heart disease
- 9





Figure 2. Causes of death among study cohort



	W	hole Population	Matched Population			
X 7 • 11	ACHD	No ACHD		ACHD	No ACHD	
Variables	(n = 189)	(n = 10,328)	p value	(n = 189)	(n = 750)	p value
Socio-demographic						
Age, median (Q1, Q3), years	63 (54, 69)	62 (55, 68)	0.49	63 (54, 69)	64 (54, 69)	0.87
Age ≥75 years	19 (10.1)	750 (7.3)	0.14	19 (10.1)	76 (10.1)	0.97
Female	75 (39.7)	2908 (28.2)	< 0.001	75 (39.7)	297 (39.6)	0.98
Married	175 (92.6)	9504 (92.0)	0.77	175 (92.6)	684 (91.2)	0.54
Medical insurance	186 (98.4)	10259 (99.3)	0.13	186 (98.4)	746 (99.5)	0.13
Medical history and risk factors						
Previous MI	19 (10.1)	1165 (11.3)	0.6	19 (10.1)	73 (9.7)	0.89

Table 1. Baseline Characteristics and treatments

Previous PCI	44 (23.3)	2743 (26.6)	0.31	44 (23.28)	189 (25.2)	0.59
Previous CABG	4 (2.1)	206 (2)	0.91	4 (2.12)	16 (2.13)	0.99
Hypertension	106 (56.1)	6655 (64.4)	0.02	106 (56.1)	503 (67.1)	< 0.001
Dyslipidemia	89 (47.1)	5175 (50.1)	0.41	89 (47.1)	386 (51.5)	0.28
Diabetes mellitus	59 (31.2)	3627 (35.1)	0.27	59 (31.2)	266 (35.5)	0.27
Renal failure history	19 (10.1)	804 (7.8)	0.25	19 (10.1)	61 (8.1)	0.4
Heart failure history	9 (4.8)	461 (4.5)	0.84	9 (4.8)	25 (3.3)	0.35
Stroke	15 (7.9)	924 (9.0)	0.63	15 (7.9)	78 (10.4)	0.31
Atrial fibrillation	6 (3.2)	142 (1.4)	0.04	6 (3.2)	11 (1.5)	0.12
Chronic obstructive pulmonary disease	1 (0.5)	53 (0.5)	0.98	1 (0.5)	2 (0.3)	0.57
Pacemaker or defibrillator	2 (1.1)	113 (1.1)	0.96	2 (1.1)	7 (0.9)	0.87
Smoking	69 (36.5)	4613 (44.7)	0.03	69 (36.5)	289 (38.5)	0.61
Alcohol	48 (25.4)	2987 (28.9)	0.29	48 (25.4)	193 (25.7)	0.92

Clinical status at admission

Acute myocardial infarction	18 (9.5)	1225 (11.9)	0.32	18 (9.5)	86 (11.5)	0.45
Hemoglobin, median (Q1, Q3), g/L	134 (120, 147)	139 (126, 150)	0.01	134 (120, 147)	137 (123, 147)	0.36
Creatinine, median (Q1, Q3), µmoI/L	76.7 (65.3, 94.1)	76.5 (66.4, 88.2)	0.61	76.7 (65.3, 94.1)	74.5 (64.2, 87.5)	0.12
LVEF, median (Q1, Q3), %	63 (60, 66)	63 (60, 66)	0.97	63 (60, 66)	64 (60, 66)	0.24
Medical treatment at admission						
Aspirin	83 (43.9)	6311 (61.1)	< 0.001	83 (43.9)	446 (59.5)	< 0.001
P2Y ₁₂ inhibitors	94 (49.7)	7304 (70.7)	< 0.001	94 (49.7)	513 (68.4)	< 0.001
Anticoagulants	18 (9.5)	209 (2)	< 0.001	18 (9.5)	20 (2.7)	< 0.001
β blocker	6 (3.2)	384 (3.7)	0.7	6 (3.2)	28 (3.7)	0.71
Diuretics	3 (1.6)	125 (1.2)	0.64	3 (1.6)	7 (0.9)	0.43
Procedural details						
Angiography	126 (66.7)	8454 (81.9)	< 0.001	126 (66.7)	604 (80.5)	< 0.001

PCI intervention	55 (29.1)	4552 (44.1)	< 0.001	55 (29.1)	301 (40.1)	0.01
CABG	27 (14.3)	972 (9.4)	0.02	27 (14.3)	62 (8.3)	0.01
Medication at discharge						
Aspirin	137 (72.5)	9115 (88.3)	< 0.001	137 (72.5)	644 (85.9)	< 0.001
Clopidogrel	77 (40.7)	5319 (51.5)	< 0.001	77 (40.7)	365 (48.7)	0.05
Ticagrelor	30 (15.9)	2513 (24.3)	0.01	30 (15.9)	171 (22.8)	0.04
OAC	32 (16.9)	457 (4.4)	< 0.001	32 (16.9)	45 (6)	< 0.001
β blocker	100 (52.9)	6227 (60.3)	0.04	100 (52.9)	457 (60.9)	0.04
ACEI/ ARB	73 (38.6)	4028 (39)	0.92	73 (38.6)	308 (41.1)	0.54
Statin	155 (82)	9356 (90.6)	< 0.001	155 (82)	678 (90.4)	< 0.001
Duration of hospitalization, median (Q1, Q3)	3 (2, 6)	3 (2, 5)	0.21	3 (2, 6)	3 (2, 5)	0.01

Values are numbers (percentages) unless otherwise indicated. Percentages may not sum to 100 due to rounding.

MI, myocardial infarction; PCI, primary percutaneous coronary intervention; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction

	V	Whole population		Matched population			
	ACHD			ACHD	No ACHD		
Outcomes	(n = 189) $(n = 10,328)$		p value	(n = 189)	(n = 750)	p value	
Death	2 (1.06)	29 (0.28)	0.05	2 (1.06)	1 (0.13)	0.04	
Cardiovascular death	2 (1.06)	27 (0.26)	0.04	2 (1.06)	1 (0.13)	0.04	
Stroke	6 (3.17)	96 (0.93)	< 0.001	6 (3.17)	9 (1.2)	0.05	
Ischemic stroke	5 (2.65)	93 (0.9)	0.01	5 (2.65)	9 (1.2)	0.14	
Intracerebral hemorrhage	1 (0.53)	3 (0.03)	< 0.001	1 (0.53)	0 (0)	0.05	
Pneumonia	1 (0.53)	45 (0.44)	0.85	1 (0.53)	2 (0.27)	0.57	

Table 2. Incidence of In-hospital Clinical Outcomes between study groups

	Death		Stroke	:	
	OR (95% CI)	p value	OR (95% CI)	p value	
ACHD	3.03 (0.65–14.13)	0.16	2.89 (1.22–6.87)	0.02	
Female	1.23 (0.47–3.25)	0.67	1.25 (0.77–2.01)	0.36	
Anemia at admission	4.57 (1.9–11.01)	< 0.001	1.08 (0.62–1.89)	0.78	
Smoking	1.6 (0.65–3.94)	0.3	0.74 (0.45–1.2)	0.22	
Hypertension	1.98 (0.85–4.57)	0.11	2.9 (1.74-4.83)	< 0.001	
Atrial fibrillation	2.81 (0.36–21.73)	0.32	N/A	N/A	
Acute myocardial infarction	19.15 (8.77–41.82)	< 0.001	1.44 (0.78–2.69)	0.24	
PCI intervention	0.38 (0.15–0.95)	0.04	0.32 (0.17–0.59)	< 0.001	
CABG	0.14 (0.04–0.5)	0.002	1.09 (0.58–2.04)	0.78	

Table 3. Risk factors of death and stroke

PCI, primary percutaneous coronary intervention; CABG, coronary artery bypass grafting